PRKN and Alzheimer disease: Consistent with their findings, we also observed overexpression of PINK1 and Parkin in the AD cell model and 7-month-old APP/PS1 mice, as determined by Western blot and immunofluorescence analyses, while the administration of M2-EXOs decreased their expression in a dose-dependent manner.